{"title":"Microfluidic Manufacture of Solid Lipid Nanoparticles: A Case Study on Tristearin-Based Systems","authors":"Giulia Anderluzzi, Y. Perrie","doi":"10.2174/2210303109666190807104437","DOIUrl":null,"url":null,"abstract":"\n\nSolid lipid nanoparticles are lipid-based carriers that can be used for a range of\ndrugs and biomolecules. However, most production methods currently used do not offer easy translation\nfrom laboratory preparation to scale-independent production.\n\n\n\nWithin this study, we have investigated the use of microfluidics to produce solid lipid\nnanoparticles and investigated their protein loading capability. In the development of this process, we\nhave investigated and identified the critical process parameters that impact on the product attributes of\nthe solid lipid nanoparticles.\n\n\n\nSolid lipid nanoparticles based on Tristearin and 1,2-Distearoyl-phosphatidylethanolaminemethyl-\npolyethyleneglycol conjugate-2000 were formulated using the NanoAssemblr® Benchtop system.\nThe flow rate ratio, total flow rate and initial protein concentration were investigated as process parameters\nand the particle size, PDI, zeta potential, drug loading and drug release were measured as\nproduct attributes.\n\n\n\nOur results demonstrate the suitability of microfluidics as a production method for solid lipid\nnanoparticles containing protein. In terms of key process parameters to consider, both the solvent to\naqueous flow rate ratio and the total flow rate were shown to have a notable impact on particle size. Protein\nloading capacity was influenced by the solvent to aqueous flow rate ratio but was similar across all\nflow rates tested.\n\n\n\nWithin this study, we outline a rapid and easy protocol for the scale-independent production\nof solid lipid nanoparticles. This process can support the rapid translation of production methods\nfrom bench to clinic.\n","PeriodicalId":11310,"journal":{"name":"Drug Delivery Letters","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Delivery Letters","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2210303109666190807104437","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 7
Abstract
Solid lipid nanoparticles are lipid-based carriers that can be used for a range of
drugs and biomolecules. However, most production methods currently used do not offer easy translation
from laboratory preparation to scale-independent production.
Within this study, we have investigated the use of microfluidics to produce solid lipid
nanoparticles and investigated their protein loading capability. In the development of this process, we
have investigated and identified the critical process parameters that impact on the product attributes of
the solid lipid nanoparticles.
Solid lipid nanoparticles based on Tristearin and 1,2-Distearoyl-phosphatidylethanolaminemethyl-
polyethyleneglycol conjugate-2000 were formulated using the NanoAssemblr® Benchtop system.
The flow rate ratio, total flow rate and initial protein concentration were investigated as process parameters
and the particle size, PDI, zeta potential, drug loading and drug release were measured as
product attributes.
Our results demonstrate the suitability of microfluidics as a production method for solid lipid
nanoparticles containing protein. In terms of key process parameters to consider, both the solvent to
aqueous flow rate ratio and the total flow rate were shown to have a notable impact on particle size. Protein
loading capacity was influenced by the solvent to aqueous flow rate ratio but was similar across all
flow rates tested.
Within this study, we outline a rapid and easy protocol for the scale-independent production
of solid lipid nanoparticles. This process can support the rapid translation of production methods
from bench to clinic.